The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features.
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Bayer; Novartis
Research Funding - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Novartis
 
Yingbei Chen
No Relationships to Disclose
 
Joshua Chaim
No Relationships to Disclose
 
Devyn Taylor Coskey
No Relationships to Disclose
 
Kaitlin Woo
No Relationships to Disclose
 
Almedina Redzematovic
No Relationships to Disclose
 
Patricia Wang
No Relationships to Disclose
 
William Lee
Stock and Other Ownership Interests - Abbott Diagnostics; Abbvie; Immunogen
 
Sujata Patil
No Relationships to Disclose
 
Ana M. Molina
Consulting or Advisory Role - AVEO; Bayer/Onyx
Research Funding - Eisai (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Eisai
 
James Hsieh
Consulting or Advisory Role - Chugai Pharma; Novartis
Research Funding - Novartis; Pfizer
 
Robert Motzer
Consulting or Advisory Role - Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline
 
Darren Richard Feldman
Consulting or Advisory Role - Bayer; Gilead Sciences (I)
Research Funding - Novartis